<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321035</url>
  </required_header>
  <id_info>
    <org_study_id>Mediking0501-1</org_study_id>
    <nct_id>NCT00321035</nct_id>
  </id_info>
  <brief_title>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital</brief_title>
  <official_title>Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pro Top &amp; Mediking Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pro Top &amp; Mediking Company Limited</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the ologen (OculusGen) Collagen Matrix is
      effective and safe to implant as an aid of glaucoma and pterygium surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ologen (OculusGen) Collagen Matrix is a porous, scaffold matrix. It is to be implanted on the
      top of the scleral flap and beneath the conjunctiva and Tenon's capsule at the end of
      trabeculectomy. The pores in the scaffold matrix range from 20 to 200µm, a size that is
      suitable for fibroblasts to grow randomly, through the body of the matrix without causing
      scarring. The space occupied by the collagen matrix scaffold creates room for the development
      of a filtration bleb. Immediately after implantation, the collagen matrix is absorbed with
      the aqueous humor that bring a certain pressure press on the top of scleral flap which makes
      the dynamic balance for the aqueous system to keep the IOP in the right side. The collagen
      matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration
      bleb to facilitate control of intraocular pressure (IOP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. the effectiveness via the reduction of IOP and the incidence of pterygium recurrence</measure>
    <time_frame>180 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the safety via the incidence of complications and adverse events.</measure>
    <time_frame>180 day</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Pterygium</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OculusGen Biodegradable Collagen Matrix Implant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Patient able to cooperate with study procedures and able to perform tests reliably

          -  Patient willing to sign informed consent

          -  Patient able and willing to complete postoperative follow-up requirements

          -  Glaucoma：one/both eyes are affected by glaucoma

          -  Pterygium： patient with pterygium

        Exclusion Criteria:

          -  Known allergic reactions to collagen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Xin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Beijing University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renmin Hospital of Beijing University</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11.</citation>
    <PMID>10937547</PMID>
  </results_reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>May 21, 2008</last_update_submitted>
  <last_update_submitted_qc>May 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2008</last_update_posted>
  <keyword>Glaucoma</keyword>
  <keyword>Pterygium</keyword>
  <keyword>collagen matrix</keyword>
  <keyword>oculusgen</keyword>
  <keyword>ologen</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>anti scarring</keyword>
  <keyword>prevent recurrence</keyword>
  <keyword>tissue engineering</keyword>
  <keyword>Aeon Astron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

